ABEONA THERAPEUTICS INC. - 8-K Filing

Abeona Therapeutics reports Q3 2026 net ZEVASKYN revenue of $13.5 million and announces acquisition of Phase 3-ready ABO-801. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 9, 2026, 11:35 UTC

Tickers: $ABEO

Read the full article at SEC EDGAR

Part of the story IDEAYA Biosciences, Inc. - 8-K Filing (42 articles)

More Regulatory news

First Digital Acquisition Corp Ltd. - 8-K Filing SEC EDGAR · November 12, 2026, 15:29 UTC
GROOVE BOTANICALS INC. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:24 UTC
Johnson Controls International plc - 10-K Filing SEC EDGAR · November 12, 2026, 15:24 UTC
OLD NATIONAL BANCORP /IN/ - 8-K Filing SEC EDGAR · November 12, 2026, 15:20 UTC
AMTECH SYSTEMS INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:16 UTC
REGIONAL HEALTH PROPERTIES, INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:09 UTC
Bitwise Avalanche ETF - 8-K Filing SEC EDGAR · November 12, 2026, 15:06 UTC
MiNK Therapeutics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:05 UTC
Future Vision II Acquisition Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC
THUNDER MOUNTAIN GOLD INC - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC